OverviewSuggest Edit

Celyad is a biopharmaceutical company, specialized in cell therapy and developing of technologies to treat severe diseases with poor prognosis. The Company focuses on immuno oncology, cardiology, and medical devices.

TypePublic
Founded2007
HQMont-Saint-Guibert, BE
Websitecelyad.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Apr 2022)87
Job Openings1
Revenue (FY, 2017)€3.5 M(-58%)
Share Price (May 2022)€1.7(-4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Celyad

Michel Lussier

Michel Lussier

Chairman, Non-Executive Director
Filippo Petti

Filippo Petti

Chief Executive Officer/CFO
Frederic Lehmann

Frederic Lehmann

VP Clinical Development and Medical Affairs
Philippe Dechamps

Philippe Dechamps

Chief Legal Officer
Philippe Nobels

Philippe Nobels

VP Human Resources
Marina Udier

Marina Udier

Independent Director
Show more

Celyad Office Locations

Celyad has offices in Mont-Saint-Guibert and New York
Mont-Saint-Guibert, BE (HQ)
2 Rue Edouard Belin
New York, NY, US
60 Broad St Suite 3502
Show all (2)

Celyad Financials and Metrics

Celyad Revenue

Embed Graph
View revenue for all periods
Celyad's revenue was reported to be €3.54 m in FY, 2017 which is a 58.5% decrease from the previous period.
EUR

Revenue (FY, 2017)

3.5m

Revenue growth (FY, 2016 - FY, 2017), %

(58.5%)

Gross profit (FY, 2017)

3.0m

Gross profit margin (FY, 2017), %

85.5%

Net income (FY, 2017)

(56.4m)

EBIT (FY, 2017)

(52.9m)

Market capitalization (12-May-2022)

37.5m

Closing stock price (12-May-2022)

1.7

Cash (31-Dec-2017)

23.3m

EV

14.8m
Celyad's current market capitalization is €37.5 m.
EURFY, 2015FY, 2016FY, 2017

Revenue

3.0k8.5m3.5m

Revenue growth, %

284000%(58%)

Cost of goods sold

1.0k53.0k515.0k

Gross profit

2.0k8.5m3.0m
EURFY, 2015FY, 2016FY, 2017

Cash

100.2m48.4m23.3m

Accounts Receivable

549.0k1.4m233.0k

Current Assets

109.4m85.4m36.4m

PP&E

1.1m3.6m3.3m
EURFY, 2015FY, 2016FY, 2017

Net Income

(29.1m)(23.6m)(56.4m)

Depreciation and Amortization

273.0k760.0k966.0k

Accounts Payable

1.1m(740.0k)(2.5m)

Cash From Operating Activities

(27.3m)(24.7m)(44.4m)
EURFY, 2015

Financial Leverage

1.4 x
Show all financial metrics

Celyad Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Celyad Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Celyad Online and Social Media Presence

Embed Graph

Celyad News and Updates

CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the First Quarter 2022 Financial Review section, the figures for cash and cash equivalents and net cash b…

Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call

MONT-SAINT-GUIBERT, Belgium, March 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will …

Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial

MONT-SAINT-GUIBERT, Belgium, March 02, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that o…

Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial

MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it has …

Celyad Oncology Provides Outlook for 2022

MONT-SAINT-GUIBERT, Belgium, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced a 2021 year-end review …

Celyad Oncology Announces January 2022 Conference Schedule

MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans …
Show more

Celyad Blogs

Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery The post Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference appeared first on Celyad Oncology.

Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

Enrollment continues in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma The post Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights appeared first on Celyad Oncolog…

Letter to Shareholders – March 2022

Dear Shareholder, Over 2021, the hard work and dedication of the entire Celyad Oncology team has helped us to continue The post Letter to Shareholders – March 2022 appeared first on Celyad Oncology.

Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights

Phase 1 IMMUNICY-1 trial demonstrated encouraging data to date for CYAD-211 including a good tolerability profile and evidence of clinical The post Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights appeared first on Celyad Oncology.

Celyad Oncology Announces February 2022 Conference Schedule

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development The post Celyad Oncology Announces February 2022 Conference Schedule appeared first on Celyad Oncology.

Transparency notification received from Tolefi SA and related persons (Article 14 §1 of the Law of 2 May 2007)

Mont-Saint-Guibert, Belgium – 17 December 2021 – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on The post Transparency notification received from Tolefi SA and related persons (Article 14 §1 of the Law of 2 May 2007) appeared first on Celyad Oncolo…
Show more

Celyad Frequently Asked Questions

  • When was Celyad founded?

    Celyad was founded in 2007.

  • Who are Celyad key executives?

    Celyad's key executives are Michel Lussier, Filippo Petti and Frederic Lehmann.

  • How many employees does Celyad have?

    Celyad has 87 employees.

  • What is Celyad revenue?

    Latest Celyad annual revenue is €3.5 m.

  • What is Celyad revenue per employee?

    Latest Celyad revenue per employee is €40.7 k.

  • Who are Celyad competitors?

    Competitors of Celyad include Bellicum Pharmaceuticals, Alnylam Pharmaceuticals and Sorrento Therapeutics.

  • Where is Celyad headquarters?

    Celyad headquarters is located at 2 Rue Edouard Belin, Mont-Saint-Guibert.

  • Where are Celyad offices?

    Celyad has offices in Mont-Saint-Guibert and New York.

  • How many offices does Celyad have?

    Celyad has 2 offices.